CRX Cyprotex

TIDMCRX

Cyprotex PLC

01 October 2014

1(st) October 2014

Cyprotex PLC

("Cyprotex" or the "Company")

Expansion of Toxicology Capabilities

Cyprotex PLC (AIM:CRX; www.cyprotex.com), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the expansion of its toxicology capabilities to include high content 3D tissue analysis and advanced mitochondrial toxicity analysis.

The introduction of these capabilities at Cyprotex follows the purchase of new instruments including a Thermo Scientific ArrayScan(TM) XTI high content screening (HCS) platform and a Seahorse XF(e) extracellular flux analyser. The investment in these technologies will allow Cyprotex to provide greater specialisation in key areas of interest in the field of toxicology and also enable the Company to expand into pharmacological efficacy research (e.g., cancer and cardiovascular models), which will unlock potential from new segments of the pharmaceutical market.

3D tissue models are becoming increasingly important in the field of pharmaceutical and cosmetics research and product development. Within the cosmetics field, 3D skin models are now approved by the regulatory authorities as in vitro alternatives to animal testing. These include MatTek's EpiDerm(TM) model which is offered by Cyprotex for skin irritation, skin corrosion and skin sensitisation testing. The characteristics of these 3D tissue models are more relevant to the in vivo situation than 2D models, and as their complexity evolves (e.g., using stem cells and/or co-culture models) these models will become more predictive, and ultimately, a critical tool in toxicological research. The ArrayScan(TM) XTI HCS platform houses a confocal microscope enabling high quality imaging of 3D cellular structures and is complementary to the Cyprotex offering. By investing in this technology Cyprotex maintains its position at the forefront of scientific research in this field.

Changes in mitochondrial function play a role in the cause of many disease conditions and are a key mechanism in drug induced toxicity. The Seahorse XF(e) platform monitors two major energy producing pathways of the cell which are linked to mitochondrial function. The introduction of this service provides new opportunities in multiple areas of research.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the expansion of the toxicology facility:

"Understanding the mechanisms of toxicology of new therapeutics remains a challenging area. Cyprotex is committed to research in this field to help our clients bring safer drugs to the market. By investing in the ArrayScan(TM) XTI and the Seahorse XF(e) we are equipped with some of the latest cutting-edge technologies, allowing us to expand our current offerings into key specialist areas."

For further information:

 
 Cyprotex PLC                                 Tel: +44 (0) 1625 505 
                                               100 
 Dr Anthony Baxter, Chief Executive Officer   ir@cyprotex.com 
  John Dootson, Chief Financial Officer        www.cyprotex.com 
  Mark Warburton, Chief Operating Officer 
  and Legal Counsel 
 
 N+1 Singer (Nomad and broker to Cyprotex)    Tel: +44 (0)20 7496 3000 
 Shaun Dobson                                 shaun.dobson@n1singer.com 
  Jen Boorer                                   jennifer.boorer@n1singer.com 
                                               www.n1singer.com 
 
 FTI Consulting                               Tel: +44 (0) 20 3727 1000 
 Simon Conway                                 cyprotex@fticonsulting.com 
  Mo Noonan                                    www.fticonsulting.com 
 

Notes to Editors

Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 900 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAWGUUWBUPCGPU

Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024